PDE4A and psoriatic arthritis: A recent prospective, open-label study (Immune Metabolic Associations in Psoriatic Arthritis) evaluated the effect of the phosphodiesterase-4 (PDE4) inhibitor apremilast on body weight and composition and observed weight loss, principally abdominal subcutaneous fat, and improvement in psoriatic disease activity independent of weight change [52].